Evidence map›Paper›PMID 33009588›Full record

ArticlePharmaceutical research2020

Use of Microfluidics to Fabricate Bioerodable Lipid Hybrid Nanoparticles Containing Hydromorphone or Ketamine for the Relief of Intractable Pain.

Minze Zhu, Andrew K Whittaker, Xingyu Jiang, Rupei Tang, Xuanyu Li, Weizhi Xu, Changkui Fu, Maree T Smith, Felicity Y Han

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Minze ZhuSchool of Pharmacy, Faculty of Health and Behavioural Sciences, The University of Queensland, Brisbane, QLD, Australia.
Andrew K WhittakerAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia.
Xingyu JiangNational Center for Nanoscience and Technology, Beijing, China.
Rupei TangEngineering Research Centre for Biomedical Materials, Anhui University, Hefei, Anhui Province, China.
Xuanyu LiNational Center for Nanoscience and Technology, Beijing, China.
Weizhi XuSchool of Biomedical Sciences, Faculty of Medicine, The University of Queensland, St Lucia Campus, Brisbane, QLD, 4072, Australia.
Changkui FuAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia.
Maree T SmithSchool of Biomedical Sciences, Faculty of Medicine, The University of Queensland, St Lucia Campus, Brisbane, QLD, 4072, Australia.
Felicity Y HanAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia. f.han@uq.edu.au.ORCID http://orcid.org/0000-0001-7260-5832
The University of Queensland · AUAnhui University · CNNational Center for Nanoscience and Technology · CNSouthern University of Science and Technology · CN

Funding

National Health and Medical Research Council APP1107723
6 · The paper itself

Abstract

purposeFor patients with intractable cancer-related pain, administration of strong opioid analgesics and adjuvant agents by the intrathecal (i.t.) route in close proximity to the target receptors/ion channels, may restore pain relief. Hence, the aim of this study was to use bioerodable polymers to encapsulate an opioid analgesic (hydromorphone) and an adjuvant drug (ketamine) to produce prolonged-release formulations for i.t. injection.

methodsA two-stage microfluidic method was used to fabricate nanoparticles (NPs). The physical properties were characterised using dynamic light scattering and transmission electron microscopy. A pilot in vivo study was conducted in a rat model of peripheral neuropathic pain.

resultsThe in vitro release of encapsulated payload from NPs produced with a polymer mixture (CPP-SA/PLGA 50:50) was sustained for 28 days. In a pilot in vivo study, analgesia was maintained over a three day period following i.t. injection of hydromorphone-loaded NPs at 50 μg. Co-administration of ketamine-loaded NPs at 340 μg did not increase the duration of analgesia significantly.

conclusionsThe two-stage microfluidic method allowed efficient production of analgesic/adjuvant drug-loaded NPs. Our proof-of-principle in vivo study shows prolonged hydromorphone analgesic for 78 h after single i.t. injection. At the i.t. dose administered, ketamine released from NPs was insufficient to augment hydromorphone analgesia.

Indexed as

MicrofluidicsAnalgesics, OpioidAnimalsDrug CompoundingHydromorphoneInjections, SpinalIntractable PainKetamineLipidsMaleNanoparticlesPolymersRatsRats, Sprague-DawleyAnalgesics, OpioidHydromorphoneKetamineLipidsPolymersbulk eroding polymersdrug deliveryintractable neuropathic painintrathecal (i.t.) injectionsurface eroding polymers

Identifiers

PMID33009588
OpenAlexW3090449026

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.